Redhill Biopharma Ltd
RDHL1.070USD
+0.040+3.88%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
3.56MMarket Cap
0.02P/E TTM
More Details of Redhill Biopharma Ltd Company
RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.
Redhill Biopharma Ltd Info
Ticker SymbolRDHL
Company nameRedhill Biopharma Ltd
IPO dateFeb 01, 2011
CEOBen-Asher (Dror)
Number of employees35
Security typeDepository Receipt
Fiscal year-endFeb 01
Address21 Ha'arba'a St.
CityTEL AVIV-YAFO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryIsrael
Postal code6473921
Phone97235413131
Websitehttps://www.redhillbio.com/
Ticker SymbolRDHL
IPO dateFeb 01, 2011
CEOBen-Asher (Dror)
Company Executives of Redhill Biopharma Ltd
Name
Name/Position
Position
Shareholding
Change
Mr. Dror Ben-Asher
Mr. Dror Ben-Asher
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Mr. Eric Swenden
Mr. Eric Swenden
Independent Director
Independent Director
--
--
Dr. Kenneth Reed, M.D.
Dr. Kenneth Reed, M.D.
Independent Director
Independent Director
--
--
Mr. Ofer Tsimchi
Mr. Ofer Tsimchi
Independent Director
Independent Director
--
--
Dr. Reza Fathi, Ph.D.
Dr. Reza Fathi, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
--
--
Mr. Gilead Raday
Mr. Gilead Raday
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Adi Frish
Mr. Adi Frish
Chief Corporate and Business Development Officer
Chief Corporate and Business Development Officer
--
--
Mr. Guy Goldberg, J.D.
Mr. Guy Goldberg, J.D.
Chief Business Officer
Chief Business Officer
--
--
Mr. Rick D. Scruggs
Mr. Rick D. Scruggs
Chief Commercial Officer, Director
Chief Commercial Officer, Director
--
--
Dr. Shmuel Cabilly, Ph.D.
Dr. Shmuel Cabilly, Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Dror Ben-Asher
Mr. Dror Ben-Asher
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Mr. Eric Swenden
Mr. Eric Swenden
Independent Director
Independent Director
--
--
Dr. Kenneth Reed, M.D.
Dr. Kenneth Reed, M.D.
Independent Director
Independent Director
--
--
Mr. Ofer Tsimchi
Mr. Ofer Tsimchi
Independent Director
Independent Director
--
--
Dr. Reza Fathi, Ph.D.
Dr. Reza Fathi, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
--
--
Mr. Gilead Raday
Mr. Gilead Raday
Chief Operating Officer
Chief Operating Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Jan 3
Updated: Sat, Jan 3
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Gagnon Securities LLC
0.35%
GAMMA Investing LLC
0.09%
Desjardins Securities Inc.
0.07%
Rhumbline Advisers Ltd. Partnership
0.03%
Other
99.46%
Shareholders
Shareholders
Proportion
Gagnon Securities LLC
0.35%
GAMMA Investing LLC
0.09%
Desjardins Securities Inc.
0.07%
Rhumbline Advisers Ltd. Partnership
0.03%
Other
99.46%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
0.44%
Research Firm
0.07%
Investment Advisor
0.04%
Other
99.45%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
36
28.22K
0.55%
-60.13K
2025Q3
38
103.50K
3.11%
-21.59K
2025Q2
39
100.72K
4.39%
-24.30K
2025Q1
45
100.27K
5.67%
-27.27K
2024Q4
61
86.70K
6.77%
-35.73K
2024Q3
77
75.64K
5.91%
-52.57K
2024Q2
82
147.72K
11.56%
-10.64K
2024Q1
84
175.94K
13.78%
+109.25K
2023Q4
94
19.30K
14.67%
-65.78K
2023Q3
106
74.17K
44.30%
+53.53K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Gagnon Securities LLC
17.82K
0.35%
+17.82K
--
Sep 30, 2025
GAMMA Investing LLC
4.83K
0.09%
+4.69K
+3476.30%
Dec 31, 2025
Desjardins Securities Inc.
3.39K
0.07%
--
--
Sep 30, 2025
Rhumbline Advisers Ltd. Partnership
1.77K
0.03%
--
--
Sep 30, 2025
BofA Global Research (US)
303.00
0.01%
--
--
Sep 30, 2025
EverSource Wealth Advisors, LLC
38.00
0%
+38.00
--
Sep 30, 2025
The Advocates
19.00
0%
+19.00
--
Sep 30, 2025
Rothschild Investment Corporation
17.00
0%
+17.00
--
Sep 30, 2025
UBS Switzerland AG
16.00
0%
+15.00
+1500.00%
Sep 30, 2025
Group One Trading, L.P.
11.00
0%
--
--
Sep 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Aug 06, 2024
Merger
25→1
Aug 06, 2024
Merger
25→1
Aug 06, 2024
Merger
25→1
Aug 06, 2024
Merger
25→1
Mar 17, 2023
Merger
40→1
Mar 17, 2023
Merger
40→1
Date
Ex-dividend Date
Type
Ratio
Aug 06, 2024
Merger
25→1
Aug 06, 2024
Merger
25→1
Aug 06, 2024
Merger
25→1
Aug 06, 2024
Merger
25→1
Mar 17, 2023
Merger
40→1
Mar 17, 2023
Merger
40→1
Mar 17, 2023
Merger
40→1
Mar 17, 2023
Merger
40→1
